Product
BIBW 2992
1 clinical trial
3 indications
Indication
EGFRIndication
HER2Indication
NSCLCClinical trial
Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2Status: Completed, Estimated PCD: 2014-06-01